Lord, Abbett & Co’s Gossamer Bio GOSS Stock Holding History

Lord, Abbett & Co’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,877	Closed	-$4.41M	–	643
2021 Q4	$4.41M	Buy	+4,877	New	+$4.63M	0.01%	562

Other funds holding GOSS

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Lord, Abbett & Co's GOSS Position: Q1 2022 in Review

Lord, Abbett & Co sold out of Gossamer Bio (GOSS) in Q1 2022, closing a stake of 4,877 shares — an estimated $4.41M sold.

Lord, Abbett & Co first reported a position in GOSS in Q4 2021 and held it in 1 quarter. The position peaked at $4.41M in Q4 2021. 139 funds tracked by Wall St. Rank hold GOSS as of Q1 2022.

Lord, Abbett & Co reported no remaining Gossamer Bio position as of Q1 2022 after selling out during the quarter.
Lord, Abbett & Co sold 4,877 Gossamer Bio shares in Q1 2022, an estimated $4.41M.
Lord, Abbett & Co first reported a position in Gossamer Bio in Q4 2021 and held it in 1 quarter.
Lord, Abbett & Co's Gossamer Bio position peaked at $4.41M in Q4 2021.
139 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2022.

Based on Lord, Abbett & Co's 13F filing for Q1 2022, filed 13 May 2022.